MCID: INS002
MIFTS: 56

in Situ Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for in Situ Carcinoma

MalaCards integrated aliases for in Situ Carcinoma:

Name: in Situ Carcinoma 12 15
Carcinoma in Situ 44 73

Classifications:



Summaries for in Situ Carcinoma

Disease Ontology : 12 A carcinoma that is an early development defined by the absence of invasion of surrounding tissues.

MalaCards based summary : in Situ Carcinoma, also known as carcinoma in situ, is related to endometrium carcinoma in situ and cervix uteri carcinoma in situ. An important gene associated with in Situ Carcinoma is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Circadian entrainment and Pathways in cancer. The drugs Nolvadex and Valstar have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and cervix, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : 76 Carcinoma in situ (CIS), also known as in situ neoplasm, is a group of abnormal cells. While they are a... more...

Related Diseases for in Situ Carcinoma

Diseases in the Lip Cancer family:

Pre-Malignant Neoplasm Lip Carcinoma in Situ
in Situ Carcinoma Eye Carcinoma in Situ

Diseases related to in Situ Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 214)
# Related Disease Score Top Affiliating Genes
1 endometrium carcinoma in situ 33.1 PGR TP53
2 cervix uteri carcinoma in situ 30.5 CDKN2A KRT17 SERPIND1 TP53
3 papillary carcinoma 29.8 CDH1 ERBB2 PGR
4 breast carcinoma in situ 29.7 BRCA1 CDH1 EGFR ERBB2 ESR1 KRT5
5 pleomorphic adenoma 29.4 ERBB2 KRT14 TP53
6 squamous cell carcinoma 29.0 CDH1 CDKN2A EGFR ERBB2 TP53
7 bile duct carcinoma 29.0 ANXA8L1 CDH1 EGFR TP53
8 adenocarcinoma 29.0 CDH1 CDKN2A EGFR ERBB2 TP53
9 papilloma 28.8 CDKN2A KRT14 KRT5 TP53
10 breast cancer 25.9 BRCA1 CDH1 EGFR ERBB2 ESR1 KIAA0100
11 stomach carcinoma in situ 11.2
12 oral cavity carcinoma in situ 11.0
13 nasal cavity carcinoma in situ 11.0
14 prostate carcinoma in situ 11.0
15 skin carcinoma in situ 11.0
16 eye carcinoma in situ 11.0
17 trachea carcinoma in situ 11.0
18 colon carcinoma in situ 11.0
19 larynx carcinoma in situ 11.0
20 bladder carcinoma in situ 11.0
21 esophagus carcinoma in situ 11.0
22 liver carcinoma in situ 11.0
23 rectum carcinoma in situ 11.0
24 vulvar syringoma 11.0 ESR1 PGR
25 lung leiomyoma 11.0 ESR1 PGR
26 endometrial clear cell adenocarcinoma 11.0 ESR1 TP53
27 vulvar benign neoplasm 11.0 ESR1 PGR
28 trigonitis 11.0 ESR1 PGR
29 vulvar leiomyoma 10.9 ESR1 PGR
30 scirrhous adenocarcinoma 10.9 ERBB2 PGR
31 breast apocrine carcinoma 10.9 ERBB2 PGR
32 vestibular gland benign neoplasm 10.9 ESR1 PGR TP53
33 bartholin's gland adenoma 10.9 ESR1 PGR TP53
34 cervical carcinosarcoma 10.8 ESR1 PGR TP53
35 adenosarcoma 10.8 ESR1 PGR TP53
36 breast mucoepidermoid carcinoma 10.8 ERBB2 PGR
37 brain ependymoma 10.8 EGFR TP53
38 gallbladder squamous cell carcinoma 10.8 ERBB2 TP53
39 gastric papillary adenocarcinoma 10.8 ERBB2 TP53
40 progesterone resistance 10.8 ESR1 FKBP4 PGR
41 glassy cell carcinoma of the cervix 10.8 ERBB2 ESR1 PGR
42 breast intraductal proliferative lesion 10.7 EGFR ERBB2
43 brain stem astrocytic neoplasm 10.7 CDKN2A TP53
44 progesterone-receptor positive breast cancer 10.7 ERBB2 ESR1 PGR
45 uterine body mixed cancer 10.7 ERBB2 PGR TP53
46 actinic cheilitis 10.7 ITGB4 TP53
47 vulvar dystrophy 10.7 CDKN2A PGR
48 comedo carcinoma 10.7 ERBB2 ESR1
49 malignant spiradenoma 10.7 KRT5 TP53
50 nosophobia 10.7 BRCA1 PGR

Graphical network of the top 20 diseases related to in Situ Carcinoma:



Diseases related to in Situ Carcinoma

Symptoms & Phenotypes for in Situ Carcinoma

MGI Mouse Phenotypes related to in Situ Carcinoma:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 CDKN2A CDH1 ANXA8L1 BRCA1 ERBB2 EGFR
2 homeostasis/metabolism MP:0005376 10.41 CDKN2A AGTR1 CDH1 BRCA1 ERBB2 EGFR
3 cardiovascular system MP:0005385 10.4 BRCA1 CDKN2A AGTR1 CDH1 ESR1 ERBB2
4 digestive/alimentary MP:0005381 10.38 CDH1 BRCA1 CDKN2A ERBB2 EGFR ESR1
5 growth/size/body region MP:0005378 10.38 BRCA1 CDKN2A AGTR1 CDH1 ESR1 ERBB2
6 mortality/aging MP:0010768 10.36 CDKN2A AGTR1 CDH1 BRCA1 ERBB2 EGFR
7 hematopoietic system MP:0005397 10.34 BRCA1 CDKN2A AGTR1 ANXA8L1 ESR1 EGFR
8 immune system MP:0005387 10.34 BRCA1 CDKN2A AGTR1 CDH1 ANXA8L1 ESR1
9 endocrine/exocrine gland MP:0005379 10.33 BRCA1 CDKN2A CDH1 ESR1 ERBB2 EGFR
10 integument MP:0010771 10.32 CDH1 BRCA1 CDKN2A ERBB2 EGFR ESR1
11 embryo MP:0005380 10.21 BRCA1 CDH1 EGFR CDKN2A ERBB2 ESR1
12 adipose tissue MP:0005375 10.14 BRCA1 AGTR1 EGFR ESR1 KRT14 NR3C1
13 craniofacial MP:0005382 10.12 EGFR ERBB2 KRT17 ITGB4 KRT5 KRT14
14 muscle MP:0005369 10.06 BRCA1 EGFR ESR1 CDKN2A ERBB2 PGR
15 neoplasm MP:0002006 10.02 BRCA1 CDKN2A CDH1 ESR1 ERBB2 EGFR
16 limbs/digits/tail MP:0005371 10 BRCA1 EGFR ERBB2 KRT5 ESR1 PGR
17 no phenotypic analysis MP:0003012 9.97 CDKN2A CDH1 EGFR ESR1 KRT5 KRT17
18 renal/urinary system MP:0005367 9.81 BRCA1 AGTR1 ESR1 EGFR ITGB4 FKBP4
19 pigmentation MP:0001186 9.73 BRCA1 EGFR CDKN2A KRT14 KRT17 TP53
20 reproductive system MP:0005389 9.7 BRCA1 CDKN2A CDH1 ESR1 ERBB2 EGFR
21 respiratory system MP:0005388 9.28 BRCA1 EGFR ESR1 CDKN2A ERBB2 ITGB4

Drugs & Therapeutics for in Situ Carcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Nolvadex 18 49 TAMOXIFEN CITRATE AstraZeneca October 1998
2
Valstar 18 VALRUBICIN Anthra Pharmaceuticals October 1998

Drugs for in Situ Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 398)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
3
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
4
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2 114977-28-5 148124
5
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
6
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
7
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2 107868-30-4 60198
8
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112809-51-5 3902
9
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
10
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 51-43-4 5816
11
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 329-65-7 838
12
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3 21645-51-2
13
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
14 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Mitomycins Phase 4,Phase 3,Phase 2,Not Applicable
18 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
23 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Interferon-alpha Phase 4,Phase 3,Phase 1,Phase 2
35 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
37 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
41 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Respiratory System Agents Phase 4,Phase 2
43 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
44 Adrenergic Agents Phase 4,Phase 2
45 Adrenergic Agonists Phase 4,Phase 2
46 Adrenergic alpha-Agonists Phase 4,Phase 2
47 Chelating Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 Adrenergic beta-Agonists Phase 4,Phase 2
49 Mydriatics Phase 4,Phase 2
50 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 720)
# Name Status NCT ID Phase Drugs
1 Can Alternative Treatment Have an Impact on Cervical Dysplasia? Unknown status NCT00842738 Phase 4
2 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
3 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
4 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
5 Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization Completed NCT02368054 Phase 4 Bupivacaine;Adrenaline
6 Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia Completed NCT02199327 Phase 4 Mitomycin C;Interferon Alfa-2b
7 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
8 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
9 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
10 Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Recruiting NCT02627248 Phase 4 Huaier Granule;Epirubicin;Docetaxel;Cyclophosphamide
11 HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions Recruiting NCT03051516 Phase 4
12 FASTER-Tlalpan Study Active, not recruiting NCT03105856 Phase 4
13 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Active, not recruiting NCT02087384 Phase 4 Placebo
14 The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Active, not recruiting NCT02629510 Phase 4 Tachosil
15 Effectiveness of Cervical Screening in HPV Vaccinated Women Enrolling by invitation NCT02149030 Phase 4
16 Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Not yet recruiting NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
17 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
18 Topical Imiquimod for Bowen's Disease of the Head and Neck Unknown status NCT00384124 Phase 2, Phase 3 Imiquimod
19 Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
20 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Unknown status NCT00321048 Phase 3
21 Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) Unknown status NCT01095198 Phase 2, Phase 3
22 Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) Completed NCT01316874 Phase 2, Phase 3 Valrubicin, 800 mg
23 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
24 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
25 Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer Completed NCT00052637 Phase 3 hexaminolevulinate
26 Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
27 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
28 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
29 RAPID: Randomized Trial of Accelerated Partial Breast Irradiation Completed NCT00282035 Phase 3
30 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
31 Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer Completed NCT01442519 Phase 3 electromotive mitomycin
32 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
33 Biological Therapy in Treating Patients With Bladder Cancer Completed NCT00003779 Phase 3
34 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Completed NCT00021255 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Herceptin;Carboplatin
35 Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer Completed NCT00006034 Phase 3 doxorubicin hydrochloride
36 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
37 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
38 Study of Docetaxel in Breast Cancer Patients Completed NCT00174707 Phase 3 epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, cyclophosphamide
39 A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting Completed NCT02560584 Phase 3 Hexaminolevulinate hydrochloride
40 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
41 Docetaxel in Node Positive Adjuvant Breast Cancer Completed NCT00688740 Phase 3 Docetaxel;5-fluorouracil;Doxorubicin;Cyclophosphamide
42 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed NCT00374322 Phase 3 lapatinib
43 Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer Completed NCT00038467 Phase 3 Tamoxifen;Exemestane
44 Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial Completed NCT02181101 Phase 3 FEC-DocGemzar adjuvant chemotherapy;FEC-Doc adjuvant chemotherapy;Zoledronic acid i.v. 2 years;Zoledronic acid i.v. 5 years
45 Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer Completed NCT00336791 Phase 3 5-Fluorouracil;Cyclophosphamide;Doxorubicin;Paclitaxel;Epirubicin
46 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed NCT00003771 Phase 3 norethindrone acetate
47 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
48 Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion Completed NCT00995020 Phase 3
49 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women Completed NCT00337818 Phase 3
50 Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit Completed NCT00237562 Phase 3

Search NIH Clinical Center for in Situ Carcinoma

Cochrane evidence based reviews: carcinoma in situ

Genetic Tests for in Situ Carcinoma

Anatomical Context for in Situ Carcinoma

MalaCards organs/tissues related to in Situ Carcinoma:

41
Breast, Testes, Cervix, Prostate, Skin, Lung, Lymph Node

Publications for in Situ Carcinoma

Articles related to in Situ Carcinoma:

(show top 50) (show all 145)
# Title Authors Year
1
Hospitalization burden associated with malignant neoplasia and in situ carcinoma in vulva and vagina during a 5-year period (2009-2013) in Spain: An epidemiological study. ( 29458181 )
2018
2
Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. ( 28094198 )
2017
3
Contamination artifact that mimics in-situ carcinoma on contrast-enhanced digital mammography. ( 28987661 )
2017
4
In situ carcinoma in a hybrid cyst: a case report. ( 27792259 )
2017
5
Hospitalizations associated with malignant neoplasia and in situ carcinoma in the anus and penis in men and women during a 5-year period (2009-2013) in Spain: An epidemiological study. ( 28708948 )
2017
6
Solid papillary carcinoma of the nipple: an in situ carcinoma or an expansive growth tumor? ( 28195265 )
2016
7
The detection of Felis catus papillomavirus 3 DNA in a feline bowenoid in situ carcinoma with novel histologic features and benign clinical behavior. ( 27423734 )
2016
8
Staging classification for cancer of the ovary and the fallopian tube should include in situ carcinoma. ( 26589439 )
2016
9
A New Hitherto Unreported Histopathologic Manifestation of Mammary Analogue Secretory Carcinoma: "Masked MASC" Associated With Low-grade Mucinous Adenocarcinoma and Low-grade In Situ Carcinoma Components. ( 26808131 )
2016
10
Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels. ( 27488105 )
2016
11
Staging classification for cancer of the ovary and the fallopian tube should include in situ carcinoma. ( 27048100 )
2016
12
Reply to staging classification for cancer of the ovary and fallopian tube should include in situ carcinoma. ( 26535793 )
2015
13
Staging classification for cancer of the ovary and fallopian tube should include in situ carcinoma. ( 26535923 )
2015
14
In situ carcinoma developed over oral lichen planus: a case report with analysis of BUB3, p16, p53, Ki67 and SOX4 expression. ( 26398519 )
2015
15
Staging classification for cancer of the ovary and the fallopian tube should include in situ carcinoma. ( 26404127 )
2015
16
5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. ( 26494415 )
2015
17
Cystic hypersecretory (in situ) carcinoma of the breast: a clinicopathologic and immunohistochemical characterization of 10 cases with clinical follow-up. ( 24121179 )
2014
18
Serous tubal in situ carcinoma (STIC) in primary peritoneal serous carcinomas. ( 23722505 )
2013
19
Genomic characterization of Felis catus papillomavirus-3: a novel papillomavirus detected in a feline Bowenoid in situ carcinoma. ( 23639476 )
2013
20
In situ carcinoma of the conjunctiva: surgical excision associated with cryotherapy. ( 24092968 )
2013
21
Loss of retinoblastoma protein, but not p53, is associated with the presence of papillomaviral DNA in feline viral plaques, Bowenoid in situ carcinomas, and squamous cell carcinomas. ( 21930804 )
2012
22
Hemosuccus pancreaticus caused by in situ carcinoma of the pancreas. ( 23012009 )
2012
23
p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. ( 21804388 )
2011
24
Head and neck in situ carcinoma: survival analysis of the Thuringian cancer registration database. ( 20227329 )
2010
25
Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer. ( 19875955 )
2010
26
Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma. ( 19521656 )
2010
27
Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. ( 19584157 )
2009
28
Intracapsular (in situ) carcinoma ex pleomorphic adenoma with unusual clinical and histological features. ( 18288478 )
2008
29
In situ carcinoma of pancreas diagnosed by EUS-FNA. ( 18278717 )
2008
30
D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma. ( 18206495 )
2008
31
Study of matrix metalloproteinases and their tissue inhibitors in ductal in situ carcinomas of the breast. ( 18983606 )
2008
32
In situ carcinoma - can we predict which patient will come back with a recurrence? ( 17996643 )
2007
33
Detection of papillomaviral sequences in feline Bowenoid in situ carcinoma using consensus primers. ( 17610489 )
2007
34
Very early cytological and DNA-cytometric diagnosis of in situ carcinoma in an immunosuppressed liver transplant recipient. ( 16393256 )
2006
35
Invasive squamous cell carcinoma arising from verrucous carcinoma. Recognition of verrucous carcinoma of skin as an in situ carcinoma. ( 16935807 )
2006
36
Very early cytological and DNA-cytometric diagnosis of in situ carcinoma in an immunosuppressed liver transplant recipient. ( 16918607 )
2006
37
An in situ carcinoma of the pancreas forming 2 invasive ductal carcinomas. ( 16025010 )
2005
38
Survival of in situ carcinoma of cervix uteri: a 50-year follow-up in Finland. ( 15386351 )
2004
39
Expression of mismatch repair proteins in invasive and in situ carcinoma of the breast. ( 15523909 )
2004
40
Human papillomavirus and extragenital in situ carcinoma. ( 15237266 )
2004
41
Heterogeneous versus homogeneous genetic nature of multiple foci of in situ carcinoma of the breast. ( 14652818 )
2003
42
Severe high-grade dysplasia and in-situ carcinoma of the common bile duct and pancreatic duct. ( 12788411 )
2003
43
Collagenous spherulosis of the breast in association with in situ carcinoma. ( 12540997 )
2002
44
Incidence of second cancers among women with in situ carcinoma of the breast. ( 14965621 )
2001
45
8. The dilemma of in situ carcinoma of the breast. ( 11777293 )
2001
46
Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. ( 11685554 )
2001
47
Solid low-grade in situ carcinoma of the breast: role of associated lesions and E-cadherin in differential diagnosis. ( 11176073 )
2001
48
MnSOD expression is less frequent in tumour cells of invasive breast carcinomas than in in situ carcinomas or non-neoplastic breast epithelial cells. ( 11592093 )
2001
49
Fine-needle aspiration cytology of the breast: Invasive vs. in situ carcinoma. ( 11466818 )
2001
50
Loss of heterozygosity among tumor suppressor genes in invasive and in situ carcinoma of the uterine cervix. ( 11240714 )
2000

Variations for in Situ Carcinoma

Expression for in Situ Carcinoma

Search GEO for disease gene expression data for in Situ Carcinoma.

Pathways for in Situ Carcinoma

Pathways related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 EGFR ESR1 FKBP4 KRT14 KRT17 PGR
2 12.63 AGTR1 CDH1 CDKN2A EGFR ERBB2 ESR1
3
Show member pathways
12.53 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
4 12.37 BRCA1 CDKN2A EGFR ERBB2 TP53
5
Show member pathways
12.22 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
6 12.15 EGFR ERBB2 ESR1 TP53
7
Show member pathways
12.08 BRCA1 CDKN2A ESR1 NR3C1 PGR
8 12.03 EGFR ERBB2 ITGB4 TP53
9 11.99 BRCA1 CDH1 EGFR ESR1 TP53
10
Show member pathways
11.81 EGFR ERBB2 ESR1 PGR
11
Show member pathways
11.76 EGFR ERBB2 ESR1
12 11.74 BRCA1 EGFR FKBP4
13
Show member pathways
11.73 ESR1 NR3C1 PGR
14 11.62 CDH1 EGFR ERBB2
15 11.62 BRCA1 CDKN2A ERBB2 TP53
16 11.56 BRCA1 ERBB2 TP53
17 11.55 EGFR ERBB2 TP53
18 11.49 BRCA1 ERBB2 ITGB4
19 11.42 CDH1 CDKN2A EGFR ERBB2 TP53
20 11.39 CDKN2A EGFR TP53
21 11.05 CDH1 EGFR ERBB2 ITGB4
22 11.01 FKBP4 KRT14 KRT17 KRT5 NR3C1 TP53
23 10.59 FKBP4 NR3C1

GO Terms for in Situ Carcinoma

Cellular components related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.85 ANXA8L1 CDH1 FKBP4 ITGB4 KRT14 KRT17
2 cytoplasm GO:0005737 9.83 BRCA1 CDH1 CDKN2A EGFR ERBB2 ESR1
3 protein-containing complex GO:0032991 9.17 BRCA1 EGFR ESR1 FKBP4 NR3C1 PPIA

Biological processes related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.91 BRCA1 CDKN2A EGFR ESR1 NR3C1 PGR
2 positive regulation of transcription, DNA-templated GO:0045893 9.63 BRCA1 CDH1 CDKN2A EGFR ESR1 TP53
3 positive regulation of cell growth GO:0030307 9.61 EGFR ERBB2 KRT17
4 steroid hormone mediated signaling pathway GO:0043401 9.58 ESR1 NR3C1 PGR
5 negative regulation of ERBB signaling pathway GO:1901185 9.49 EGFR ERBB2
6 replicative senescence GO:0090399 9.48 CDKN2A TP53
7 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.46 ESR1 TP53
8 negative regulation of immature T cell proliferation in thymus GO:0033088 9.32 CDKN2A ERBB2
9 cellular response to indole-3-methanol GO:0071681 9.26 BRCA1 CDH1
10 epidermis development GO:0008544 9.26 EGFR KRT14 KRT17 KRT5
11 hemidesmosome assembly GO:0031581 8.8 ITGB4 KRT14 KRT5

Molecular functions related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.77 CDKN2A EGFR ESR1 NR3C1 TP53
2 protein phosphatase binding GO:0019903 9.58 EGFR ERBB2 TP53
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGFR ERBB2 ESR1
4 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.43 EGFR ERBB2
5 steroid hormone receptor activity GO:0003707 9.43 ESR1 NR3C1 PGR
6 enzyme binding GO:0019899 9.35 BRCA1 EGFR ESR1 PGR TP53
7 nitric-oxide synthase regulator activity GO:0030235 9.16 EGFR ESR1
8 steroid binding GO:0005496 8.8 ESR1 NR3C1 PGR

Sources for in Situ Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....